The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 1, 1999, Pages 61-65

  Carter, K C ^a   Baillie, A J ^a   Mullen, A B ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STIBOGLUCONATE SODIUM;

ANIMAL CELL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; IMMUNOPHENOTYPING; INFECTION PREVENTION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; VISCERAL LEISHMANIASIS;

EID: 0032899453     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.1.61-65.1999     Document Type: Article

References (27)

1. Alvar, J. 1994. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol. Today 10:160-163.
2. Banduwardene, R., A. B. Mullen, and K. C. Carter. 1997. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations. Int. J. Immunopharmacol. 19:195-203.
3. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
4. Bickle, Q. D. 1982. Studies on the relationship between the survival of Schistosoma mansoni larvae in mice and the degree of resistance produced. Parasitology 84:111-122.
5. Blackwell, J. M., M. B. Roberts, and J. Alexander. 1985. Response of BALB/c mice to leishmanial infection. Curr. Top. Microbiol. 122:97-106.
6. Blackwell, J. M. 1988. Protozoan infections, p. 103-151. In D. Wakelin and J. M. Blackwell (ed.), Genetics of resistance to bacterial and parasitic infection. Taylor and Francis, London, United Kingdom.
7. Bradley, D. J. 1974. Genetic control of natural resistance to Leishmania donovani. Nature 250:353-354.
8. Bradley, D. J., and J. Kirkley. 1977. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30:119-129.
9. Carter, K. C., A. J. Baillie, J. Alexander, and T. F. Dolan. 1988. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ dependent. J. Pharm. Pharmacol. 40:370-373.
10. Carter, K. C., G. Gallagher, A. J. Baillie, and J. Alexander. 1989. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur. J. Immunol. 19:779-782.
11. Carter, K. C., T. F. Dolan, J. Alexander, A. J. Baillie, and C. McColgan. 1989. Visceral leishmaniasis: drug carrier characteristics and the ability to clear parasites from the spleen, liver and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 41:87-91.
12. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
13. Collins, M., A. J. Baillie, and K. C. Carter. 1992. Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection. II. Changes in tissue drug distribution. Int. J. Pharm. 83:251-256.
14. Collins, M., K. C. Carter, A. J. Baillie, and J. O'Grady. 1993. The distribution of free and non-ionic vesicular sodium stibogluconate in the dog. J. Drug Targeting 1:133-142.
15. Elassad, A. M. S., S. A. Younis, M. Siddig, J. Grayson, E. Petersen, and H. W. Ghalib. 1994. The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients. Clin. Exp. Immunol. 95:294-299.
16. El-On, J., A. Witztum, and L. F. Schnur. 1986. Protection of guinea pigs against cutaneous leishmaniasis by combined infection and chemotherapy. Infect. Immun. 51:704-706.
17. Gregoriadis, G., and A. C. Allison (ed.). 1980. Liposomes in biological systems. Wiley, New York, N.Y.
18. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
19. Murray, H. W., S. M. Carriero, and D. M. Donelly. 1986. Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis. Infect. Immun. 54: 487-493.
20. Murray, H. W., J. J. Stern, K. Welte, B. Y. Rubin, S. M. Carriero, and C. F. Nathan. 1987. Experimental visceral leishmaniasis: production of interleukin-2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin-2 and interferon-γ. J. Immunol. 138:2290-2297.
21. Murray, H. W. 1994. Cytokines in the treatment of leishmaniases. Baillieres Clin. Infect. Dis. 1:127-143.
22. Ribera, E. R., I. Ocana, J. de Otero, E. Cortes, I. Gasser, and A. Pahissa. 1996. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am. J. Med. 100:496-501.
23. Rosenthal, E., P. Marty, I. Poizot-Martin, J. Reynes, F. Praylong, A. Lafeuillade, D. Jaubert, O. Boulat, J. Dereure, F. Gambarelli, G. A. Steut, J. A. Gastaut, P. Dujardin, P. Dellamonica, and J. P. Cassuto. 1995. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. R. Soc. Trop. Med. Hyg. 89:159-162.
24. Sacks, D. L., J. Louis, and D. F. Wirth. 1993. Leishmaniasis, p. 237-268. In K. S. Warren (ed.), Immunology and molecular biology of parasitic infections. Blackwell Scientific, Oxford, United Kingdom.
25. + cells in experimental visceral leishmaniasis. J. Immunol. 140:3971.
26. Ward, R. J., C. D. Black, and G. J. Watson. 1979. Determination of antimony in biological materials by electrothermal atomic absorption spectroscopy. Clin. Chim. Acta 99:143-152.
27. Williams, D. M., K. C. Carter, and A. J. Baillie. 1995. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J. Drug Targeting 3:1-7.